Biofrontera FY25 operating loss narrows 35.4% to EUR 1 million; revenue rises to EUR 13.2 million
PUBT · 04/17 22:23
Share
Listen to the news
- Biofrontera posted net loss of EUR 4 million, narrowing from EUR 4.4 million.
- Revenue rose 8.3% to EUR 13.2 million.
- EBITDA loss widened to EUR 819,000 from EUR 716,000.
- Ameluz grew more than 25% in Germany for a third straight year, reaching 73% market share; U.S.-related assets and liabilities were transferred to Biofrontera Inc. effective June 1, 2025, with 2025 earn-out of EUR 1.8 million.
- Guidance for 2026 calls for revenue of EUR 14 million to EUR 16 million, adjusted EBITDA of EUR 3.5 million to EUR 5.1 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved